Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma--three cases

Anticancer Res. 2006 Nov-Dec;26(6C):4851-5.

Abstract

The optimal chemotherapeutic regimen for thymic carcinoma remains uncertain and the utility of salvage therapy has also not been reported. Three cases of unresectable and locally advanced thymic carcinoma, resistant to prior chemotherapy with cisplatin are reported. These patients were treated with carboplatin and paclitaxel chemotherapy, as salvage chemotherapy. Although concomitant thoracic radiotherapy was performed in one patient, two showed a partial response and the other showed a minor response after carboplatin and paclitaxel chemotherapy. Thymic carcinoma is sensitive to platinum-based chemotherapy and paclitaxel appears to have significant activity against thymic carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Salvage Therapy
  • Thymus Neoplasms / drug therapy*

Substances

  • Carboplatin
  • Paclitaxel
  • Cisplatin